Hengrui Medicine's Ricatumab New Indication Application Granted Priority Review
nashnova research
Hengrui Medicine's ADC drug SHR-A1811 (riconecibart) has been accepted for review — and granted priority review — by China's NMPA for first-line HER2-positive breast cancer, backed by Phase III data showing significant PFS improvement over the current standard regimen.
What is this filing about?
Hengrui's subsidiary Suzhou ShengDiYa submitted a new-indication marketing application for injectable SHR-A1811 — an ADC (antibody-drug conjugate, a drug that delivers chemotherapy directly to tumor cells like a guided missile) — and the NMPA has accepted it.
The new indication targets recurrent or metastatic HER2-positive breast cancer patients who have not received prior systemic therapy — a first-line treatment setting.
This means → SHR-A1811 is moving from a later-line option to a potential front-line contender, competing head-to-head with the current standard THP regimen (docetaxel + trastuzumab + pertuzumab).
Why did it receive priority review?
The application has been included in the priority review program, which could significantly shorten the review timeline.
The filing rests on a Phase III trial coded SHR-A1811-307: multi-center, randomized, open-label, active-controlled, involving 75 sites across China, co-led by Professor Jiang Zefei of PLA General Hospital and Professor Yin Yongmei of Jiangsu Province People's Hospital.
The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR). Results showed SHR-A1811 — with or without pertuzumab — significantly extended PFS and reduced the risk of disease progression or death.
What can this drug already treat?
SHR-A1811 currently holds three approved indications in China: HER2-mutant advanced non-small-cell lung cancer, previously treated HER2-positive advanced breast cancer (later-line), and previously treated HER2-positive colorectal cancer.
In plain terms = it already has a seat at the table in lung, colorectal, and later-line breast cancer. This filing is for first-line breast cancer — the highest-value indication of them all.
What does this mean for Hengrui?
If approved, SHR-A1811's breast-cancer coverage extends from later-line to first-line, directly expanding the addressable patient population and the drug's commercial ceiling.
Priority review status shortens the wait; the review outcome will be a pivotal milestone for sizing this product's commercial potential.
This reflects Hengrui's ADC strategy shifting from filling gaps to contesting the most competitive frontline battlegrounds.
市场有风险，内容仅供研究参考，不构成投资建议。